Pharmaceuticals News and Research

RSS

IOTA NanoSolutions secures funding for commercialisation of ContraSol technology

IOTA NanoSolutions Limited, a specialist formulation company, is pleased to announce today that it has completed a financing round to support the commercialisation of its proprietary nanodispersion formation technology, ContraSol™. New investor, QIB(UK) Plc joins Unilever Ventures Limited (UV) in this financing round.

28 Jun 2011

Bio-Nucleonics' generic Metastron, an option for metastatic cancer bone pain therapy

Bio-Nucleonics' lead product Strontium Chloride Sr-89 Injection USP (Strontium-89), which is the generic version of Metastron®, is an option to consider for metastatic cancer bone pain therapy, typically caused by advanced stage breast, prostate or lung cancer.

28 Jun 2011

AMRI, Proteros ink new partnership

AMRI and Proteros Biostructures GmbH announced today that they have signed an agreement for a joint offering to the life sciences industry. Proteros, an expert in the field of protein crystallization and X-ray structural analysis, provides services that complement AMRI's existing drug discovery capabilities in chemistry, in vitro biology, drug metabolism and pharmacokinetics services.

28 Jun 2011

Tibotec, Gilead Sciences enter license agreement for new combination product of PREZISTA and cobicistat

Tibotec Pharmaceuticals today announced that it has entered into a license agreement with Gilead Sciences, Inc., for the development and commercialization of a new once-daily single tablet fixed-dose antiretroviral combination product containing Tibotec's protease inhibitor PREZISTA® (darunavir) and Gilead's cobicistat, an investigational pharmacoenhancing or "boosting" agent.

28 Jun 2011

Nimbus Discovery closes $24 million Series A financing

Nimbus Discovery LLC, a biopharmaceutical company using state-of-the-art computational technology to discover novel medicines against exciting but previously inaccessible disease targets, today announced the close of a $24M Series A financing.

28 Jun 2011

BioLineRx initiates enrollment in BL-1020 Phase II/III trial against schizophrenia

BioLineRx, a biopharmaceutical development company, announced today the enrollment of the first patient in the Phase II/III CLARITY clinical trial of BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia.

28 Jun 2011

Merck, UPS extend logistics and distribution agreement

UPS and Merck, known as MSD outside the United States and Canada, today announced that the companies have significantly broadened their existing distribution and logistics agreement to include aspects of Merck's global supply chain around the world.

28 Jun 2011

MedPro launches pre-filled safety syringe

MedPro Safety Products, Inc., a leading developer of transformational technologies that enable safer medication delivery and blood collection, today announced the introduction of its pre-filled safety syringe.

28 Jun 2011

University of Nottingham, Malaysian Government to co-host Crops for the Future Research Centre

The University of Nottingham Malaysia Campus is to co- host the first ever Crops for the Future Research Centre (CFFRC) in partnership with the Government of Malaysia.

28 Jun 2011

Janssen, Jubilant partner for drug discovery in the field of neuroscience

Jubilant Discovery Services Inc., Bedminster, New Jersey, a Jubilant Life Sciences Company, announced today that it has entered into a drug discovery alliance with Janssen Pharmaceutica N.V., Beerse, Belgium, that will aim to deliver preclinical candidates to Janssen. The alliance is set to span an initial period of 3 years and will focus on multiple targets in the area of neuroscience.

28 Jun 2011

Biolauncher, Isogenica and Cresset enter joint venture to develop drug discovery platform

Isogenica Ltd today announced a collaborative joint venture with Biolauncher Ltd and Cresset Biomolecular Discovery Ltd to develop an innovative end-to-end therapeutic discovery platform.

28 Jun 2011

DSM introduces Kremer Method for rapid, cost effective production of biopharmaceuticals

Royal DSM, the global Life Sciences and Materials Sciences company, today announced the introduction of the Kremer Method, an innovative proprietary technology developed by DSM scientists which improves downstream processing of monoclonal antibodies (mAbs) for faster and more cost effective production of biopharmaceuticals

28 Jun 2011

Yale University: Gabapentin clinical study on epilepsy may have been a 'seeding trial'

Yale School of Medicine researchers have found that a clinical trial of the epilepsy drug gabapentin may have been a "seeding trial" used by a pharmaceutical company to promote the drug and increase prescriptions, according to a report in the June issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

28 Jun 2011

Researchers, policy experts to examine issue of declining enrollment in clinical trials

Leading researchers and policy experts from across the country will come together June 27 and June 28 at Mount Sinai School of Medicine in New York to examine the issue of declining enrollment in clinical trials.

28 Jun 2011

Microbix renegotiates key terms of Hunan influenza vaccine joint venture

Microbix Biosystems Inc., a biotechnology company commercializing novel technologies for influenza vaccine manufacturing and biological products announced today that it is renegotiating key terms of the original joint venture agreement with their Joint Venture partner Hunan Biopharmaceutical Co. Ltd.

28 Jun 2011

Circulation journal publishes Celladon's MYDICAR Phase 2 trial on advanced heart failure

Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announces that the data from its completed Phase 2 CUPID clinical study of MYDICAR for the treatment of advanced heart failure is being published today online in Circulation, an American Heart Association journal.

28 Jun 2011

Positive preliminary results from Anacor's AN2728 Phase 2b trial on psoriasis

Anacor Pharmaceuticals announced today preliminary results from its Phase 2b trial of AN2728 for the treatment of mild-to-moderate plaque-type psoriasis.

28 Jun 2011

Australian Nobel Prize winner closer to delivering vaccines in food after positive first study in humans

The Australian scientist who won a Nobel Prize for identifying a cancer-causing stomach bacterium, today said a clinical trial had shown that some strains of the bacteria (Helicobacter pylori or H. pylori) were safe and well tolerated in humans.

27 Jun 2011

New and effective diabetes drug seeking approval

A new drug for diabetes from Bristol-Myers Squibb Co. and AstraZeneca PLC was effective in lowering blood sugar. The pharmaceutical drug makers are looking for approval for the drug, dapagliflozin, as the first in new class of pills designed to lower blood sugar by increasing the amount of glucose excreted in the urine.

27 Jun 2011

Nile completes dosing in Part B of cenderitide Phase I study for ADHF

Nile Therapeutics, Inc., a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced that it has completed dosing the first patient in Part B of the ongoing Phase I study.

27 Jun 2011

Pharmaceuticals News and Research

IOTA NanoSolutions secures funding for commercialisation of ContraSol technology

Bio-Nucleonics' generic Metastron, an option for metastatic cancer bone pain therapy

AMRI, Proteros ink new partnership

Tibotec, Gilead Sciences enter license agreement for new combination product of PREZISTA and cobicistat

Nimbus Discovery closes $24 million Series A financing

BioLineRx initiates enrollment in BL-1020 Phase II/III trial against schizophrenia

Merck, UPS extend logistics and distribution agreement

MedPro launches pre-filled safety syringe

University of Nottingham, Malaysian Government to co-host Crops for the Future Research Centre

Janssen, Jubilant partner for drug discovery in the field of neuroscience

Biolauncher, Isogenica and Cresset enter joint venture to develop drug discovery platform

DSM introduces Kremer Method for rapid, cost effective production of biopharmaceuticals

Yale University: Gabapentin clinical study on epilepsy may have been a 'seeding trial'

Researchers, policy experts to examine issue of declining enrollment in clinical trials

Microbix renegotiates key terms of Hunan influenza vaccine joint venture

Circulation journal publishes Celladon's MYDICAR Phase 2 trial on advanced heart failure

Positive preliminary results from Anacor's AN2728 Phase 2b trial on psoriasis

Australian Nobel Prize winner closer to delivering vaccines in food after positive first study in humans

New and effective diabetes drug seeking approval

Nile completes dosing in Part B of cenderitide Phase I study for ADHF

Free eBook - From lab to market: Accelerate your bioprocessing journey eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence